MedTrace Logo

The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring

NCT02437760 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2015-05-08

No results posted yet for this study

Summary

The tumor associated CA-125antigen for diagnosis and follow-up of ovarian cancer was well defined. Increased serum CA125 level may have many diagnoses other than ovarian cancer, including breast, colorectal and lung cancer. 80% lung cancer patients were diagnosed at advanced stage. Malignant pleural effusion secondary to lung cancer represented the condition of cancer cell involved pleura.

The CA-125 level may reflect the extent of tumor involved in pleura (tumor burden), it could be correlated with the prognosis. This study was performed to examine the properties of CA-125 by measuring pleural and blood CA-125 levels in lung cancer with or without malignant pleural effusion; meanwhile to examine whether the rate of decline in CA 125 during primary therapy as a surrogate indicator for survival.

Conditions

Interventions

OTHER

serum and pleural effusion CA-125 level

serum and pleural effusion(if exist) CA-125 are collected: * at time of diagnosis * every 3 month during treatment * stop at the progression or after 12 months

Sponsors & Collaborators

  • E-DA Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-02-28
Completion
2018-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02437760 on ClinicalTrials.gov